The US Food and Drug Administration’s work to modernize and streamline its OTC monograph system has reached the point in its fourth year that the agency, for the first time, published user fee rates for change requests before the start of fiscal year and separate from facility fees.
“The agency anticipates a greater likelihood of OMOR [OTC monograph order request] submissions compared to prior fiscal years,” said a Center
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?